These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
452 related items for PubMed ID: 15667875
1. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors. Lee CM, Lee RJ, Handrahan DL, Sause WT. Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875 [Abstract] [Full Text] [Related]
2. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Zapatero A, García-Vicente F, Modolell I, Alcántara P, Floriano A, Cruz-Conde A, Torres JJ, Pérez-Torrubia A. Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1343-51. PubMed ID: 15275719 [Abstract] [Full Text] [Related]
3. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. J Urol; 2001 Sep 01; 166(3):876-81. PubMed ID: 11490237 [Abstract] [Full Text] [Related]
4. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD. Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):735-42. PubMed ID: 14967428 [Abstract] [Full Text] [Related]
5. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD. Int J Radiat Oncol Biol Phys; 2005 Jul 01; 62(3):706-13. PubMed ID: 15936549 [Abstract] [Full Text] [Related]
6. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC. Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1019-34. PubMed ID: 15752881 [Abstract] [Full Text] [Related]
7. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA. Int J Radiat Oncol Biol Phys; 2005 Sep 01; 63(1):141-9. PubMed ID: 16111582 [Abstract] [Full Text] [Related]
8. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW. Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1297-308. PubMed ID: 16029785 [Abstract] [Full Text] [Related]
9. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Peeters ST, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PC, Lebesque JV. Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1142-52. PubMed ID: 15939547 [Abstract] [Full Text] [Related]
10. Short-course, intensity-modulated radiotherapy for localized prostate cancer. Kupelian PA, Willoughby TR. Cancer J; 2001 Nov 15; 7(5):421-6. PubMed ID: 11693901 [Abstract] [Full Text] [Related]
11. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E. Urology; 2005 Jan 15; 65(1):95-100. PubMed ID: 15667872 [Abstract] [Full Text] [Related]
12. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer. Teh BS, Dong L, McGary JE, Mai WY, Grant W, Butler EB. Med Dosim; 2005 Jan 15; 30(1):25-30. PubMed ID: 15749008 [Abstract] [Full Text] [Related]
13. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B. Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):318-28. PubMed ID: 15667949 [Abstract] [Full Text] [Related]
16. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Akimoto T, Muramatsu H, Takahashi M, Saito J, Kitamoto Y, Harashima K, Miyazawa Y, Yamada M, Ito K, Kurokawa K, Yamanaka H, Nakano T, Mitsuhashi N, Niibe H. Int J Radiat Oncol Biol Phys; 2004 Nov 15; 60(4):1033-9. PubMed ID: 15519772 [Abstract] [Full Text] [Related]
19. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J. Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):400-8. PubMed ID: 15667959 [Abstract] [Full Text] [Related]
20. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Jereczek-Fossa BA, Zerini D, Vavassori A, Fodor C, Santoro L, Minissale A, Cambria R, Cattani F, Garibaldi C, Serafini F, Matei VD, de Cobelli O, Orecchia R. Int J Radiat Oncol Biol Phys; 2009 May 01; 74(1):115-25. PubMed ID: 19004572 [Abstract] [Full Text] [Related] Page: [Next] [New Search]